Tokai Pharmaceuticals Inc., a Cambridge biopharmaceutical company focused on developing new treatments for prostate cancer, announced the appointment of Jodie Morrison to the position of chief executive.
Morrison’s appointment follows the recent departure of former president and chief executive officer Martin Williams, who has left the company to pursue other opportunities, the company said in a press release.
Morrison has held multiple positions of increasing responsibility during her nearly seven years at Tokai, most recently serving as chief operating officer and vice president of clinical affairs.
“Tokai has made impressive progress under Jodie’s clinical and operational leadership since 2006,” Seth Harrison, MD, chairman of the Tokai board of directors and managing general partner of Apple Tree Partners, said in a statement. “This is a very exciting time for Tokai as the company continues to advance its lead prostate cancer drug galeterone in the ongoing ARMOR2 Phase 2 study. We believe galeterone has the potential to be an important new treatment option for patients with advanced prostate cancer, and we are confident in Jodie’s ability to continue to execute Tokai’s goals and drive the late-stage clinical development of this program.”
Tokai is backed by Apple Tree Partners and Novartis Venture Fund.